폐암 (NSCLC) | 바이오모아

ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3

효능 ORR 33.3%임상시험 12상태 RECRUITING

AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5

효능 ORR 95%임상시험 648상태 RECRUITING

AntibodyAHotEli Lilly-linkersPhase 2

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Advanced Solid Tumor; NSCLC · EGFR

#EGFR#Antibody#Phase2#인기#항체+5

효능 ORR 70.6%임상시험 166상태 ACTIVE

AntibodyAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5

효능 ORR 36.3%임상시험 65상태 ACTIVE

ADCBiologicstaleCullinan Therapeutics Inc.Phase 1

Dato-DXd (Datopotamab deruxtecan-dlnk, Datopotamab deruxtecan-dlnk (Dato-DXd))

Advanced Solid Tumor; NSCLC · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 74%임상시험 30상태 RECRUITING

ADCBiologicstaleBioNTech SEPhase 3

Pumitamig (Pumitamig)

Non-small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 19상태 RECRUITING

ADCBiologicstaleAmgenPhase 2

YL201 (YL201)

Small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 12상태 RECRUITING

AntibodystaleJeffrey ClarkePhase 1

AMG 479, Everolimus, Panitumumab (AMG 479, Everolimus, Panitumumab)

Advanced Solid Tumors, Non-small Cell Lung Cancer · Advanced Solid Tumors, Non-small Cell Lu

#AdvancedSolidTumorsNon-smallCell#Antibody#Phase1#항체#면역항체+4

임상시험 1상태 ACTIVE

ADCBiologicstaleMacroGenicsPhase 1

MGC028 (MGC028)

Advanced Solid Tumors; NSCLC Adenocarcinoma · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING